Login / Signup

Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System.

Sara CeccoStefano PulighedduMichele FusaroliLorenzo GerratanaMiao YanClaudio ZamagniFabrizio De PontiEmanuel Raschi
Published in: Targeted oncology (2024)
The heterogeneous spectrum of post-marketing toxicities for ADCs used in breast cancer, as emerging from the FAERS, is largely in line with preapproval evidence. Although causality cannot be proved, we call for increased awareness by oncologists on potential serious unexpected reactions, including early onset of septic shock and neutropenic colitis with SG, and late emergence of pulmonary embolism with T-DM1.
Keyphrases
  • pulmonary embolism
  • early onset
  • septic shock
  • late onset
  • adverse drug
  • inferior vena cava
  • risk assessment
  • human health
  • skeletal muscle
  • cancer therapy
  • advanced cancer
  • breast cancer risk
  • climate change